{"id":270,"date":"2021-04-21T00:48:36","date_gmt":"2021-04-21T05:48:36","guid":{"rendered":"https:\/\/www.cd-bioparticles.com\/blog\/?p=270"},"modified":"2021-04-21T00:48:36","modified_gmt":"2021-04-21T05:48:36","slug":"researchers-find-nanoparticle-flu-vaccine-blocks-seasonal-and-pandemic-strains","status":"publish","type":"post","link":"https:\/\/www.cd-bioparticles.com\/blog\/nanoparticles\/researchers-find-nanoparticle-flu-vaccine-blocks-seasonal-and-pandemic-strains\/","title":{"rendered":"Researchers Find Nanoparticle Flu Vaccine Blocks Seasonal and Pandemic Strains"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"aligncenter\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"\/blog\/wp-content\/uploads\/2021\/04\/Nanoparticle-Flu-Vaccine-Blocks-Seasonal-and-Pandemic-Strains-1024x683.jpg\" alt=\"\" class=\"wp-image-271\" srcset=\"\/blog\/wp-content\/uploads\/2021\/04\/Nanoparticle-Flu-Vaccine-Blocks-Seasonal-and-Pandemic-Strains-1024x683.jpg 1024w, \/blog\/wp-content\/uploads\/2021\/04\/Nanoparticle-Flu-Vaccine-Blocks-Seasonal-and-Pandemic-Strains-300x200.jpg 300w, \/blog\/wp-content\/uploads\/2021\/04\/Nanoparticle-Flu-Vaccine-Blocks-Seasonal-and-Pandemic-Strains-768x512.jpg 768w, \/blog\/wp-content\/uploads\/2021\/04\/Nanoparticle-Flu-Vaccine-Blocks-Seasonal-and-Pandemic-Strains-120x80.jpg 120w, \/blog\/wp-content\/uploads\/2021\/04\/Nanoparticle-Flu-Vaccine-Blocks-Seasonal-and-Pandemic-Strains.jpg 1269w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n\n\n<p>In a recent study, researchers have developed an\nexperimental influenza vaccine that can protect animals from various seasonal\nand pandemic influenza strains. The vaccine is currently developing in the\ndirection of clinical testing. If proven to be safe and effective, these\nnext-generation influenza vaccines could replace current seasonal options by\nproviding protection against more strains that current vaccines cannot\nadequately cover. <\/p>\n\n\n\n<p>This new study was published in the March 24 issue of the\njournal <em>Nature<\/em>, examining in detail the design of new influenza vaccines\nand how they protect mice, ferrets and non-human primates, with the title of <em>Quadrivalent\ninfluenza nanoparticle vaccines induce broad protection<\/em>. This study was led\nby researchers from the University of Washington School of Medicine and the\nVaccine Research Center part of the National Institute of Allergy and\nInfectious Diseases at the National Institutes of Health.<\/p>\n\n\n\n<p>Influenza vaccines that confer broad and durable protection\nagainst diverse viral strains would have a major effect on global health, as\nthey would lessen the need for annual vaccine reformulation and immunization.\nIn this paper, the researchers show that computationally designed,\ntwo-component nanoparticle immunogens induce potently neutralizing and broadly\nprotective antibody responses against a wide variety of influenza viruses. <\/p>\n\n\n\n<p>The nanoparticle immunogens contain 20 haemagglutinin\nglycoprotein trimers in an ordered array, and their assembly <em>in vitro<\/em>\nenables the precisely controlled co-display of multiple distinct haemagglutinin\nproteins in defined ratios. Nanoparticle immunogens that co-display the four\nhaemagglutinins of licensed quadrivalent influenza vaccines elicited antibody\nresponses in several animal models against vaccine-matched strains that were\nequivalent to or better than commercial quadrivalent influenza vaccines, and\nsimultaneously induced broadly protective antibody responses to heterologous\nviruses by targeting the subdominant yet conserved haemagglutinin stem. The combination\nof potent receptor-blocking and cross-reactive stem-directed antibodies induced\nby the nanoparticle immunogens makes them attractive candidates for a supra-seasonal\ninfluenza vaccine candidate with the potential to replace conventional seasonal\nvaccines.<\/p>\n\n\n\n<p>It is estimated that the influenza virus causes\n290,000-650,000 deaths per year. Existing influenza vaccines need to be used\nseasonally and usually cannot prevent multiple circulating influenza strains.\nIn order to create an improved version of the flu vaccine, the research team\nlinked hemagglutinin proteins from four different influenza viruses to\ncustomized protein nanoparticles. Compared with traditional influenza vaccines,\nthis method can control the molecular configuration of the obtained vaccines\nunprecedentedly and produce an improved immune response. The new nanoparticle\nvaccine contains the same four hemagglutinin proteins as the commercially\navailable quadrivalent influenza vaccine, resulting in neutralizing antibody\nresponses to vaccine-matched strains that are equivalent or better to\ncommercial vaccines in mice, ferrets, and non-human primates. The nanoparticle\nvaccines (rather than commercial vaccines) can also induce protective antibody\nresponses against viruses not contained in the vaccine formulation.<\/p>\n\n\n\n<p>About the author: With years of experience in the pharmaceutical and life science sector, CD Bioparticles is a leading manufacturer and supplier of various <a href=\"https:\/\/www.cd-bioparticles.com\/product\/nanoparticles-list-4.html\">nanoparticles<\/a> that can be widely used in biology and medicine fields, including colloidal gold nanoparticles, silver nanoparticles, silica nanoparticles, titania nanoparticles, inorganic fluorescent nanoparticles (quantum dots and upconversion nanocrystals), and biodegradable polymer nanoparticles. Our nanoparticles are manufactured with different shapes and sizes, and the particle surface can be coated, functionalized or conjugated with biomolecules for research use. <\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>Reference<br> Boyoglu-Barnum, S., Ellis, D., Gillespie, R. A., Hutchinson, G. B., Park, Y. J., Moin, S. M., \u2026 &amp; Kanekiyo, M. (2021). Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature, 1-6. <\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>In a recent study, researchers have developed an experimental influenza vaccine that can protect animals from various seasonal and pandemic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,2],"tags":[39,5],"class_list":["post-270","post","type-post","status-publish","format-standard","hentry","category-applications","category-nanoparticles","tag-influenza-virus","tag-nanoparticles"],"_links":{"self":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/comments?post=270"}],"version-history":[{"count":1,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/270\/revisions"}],"predecessor-version":[{"id":272,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/270\/revisions\/272"}],"wp:attachment":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/media?parent=270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/categories?post=270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/tags?post=270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}